NeMadipine B
|
非洛地平杂质B
|
79925-38-5
|
IMpurity A of Falecalcitriol
|
氟骨化醇Trans杂质
|
303015-34-1
|
BAY-M 5579
|
1,4-二氢-2,6-二甲基-4-(3-硝基苯基)-3,5-吡啶二羧酸单乙酯
|
74936-73-5
|
Paricalcitol
|
帕立骨化醇
|
131918-61-1
|
2β-trans-eldecalcitol
|
艾地骨化醇Trans杂质
|
861996-34-1
|
1,3-Cyclohexanediol, 4-methylene-5-[(2E)-2-[(1R,3aS,7aR)-octahydro-1-[(1S)-5-hydroxy-1,5-dimethylhexyl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-, (1R,3S,5Z)-
|
骨化三醇20S杂质
|
134523-84-5
|
Calcitriol
|
骨化三醇
|
32222-06-3
|
(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methyl-6-triethylsilyloxyheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-one
|
骨化三醇CD环14-epi-杂质
|
1101133-55-4
|
Linagliptin Impurity C
|
利格列汀杂质C
|
1791405-13-4
|
Calcitriol EP impurity A
|
骨化三醇Trans杂质
|
73837-24-8
|
(24R)-paricalcitol
|
帕立骨化醇24R杂质
|
132015-95-3
|
2-(3-hydroxypropoxy)-1,25-dihydroxyvitamin D3
|
艾地骨化醇
|
104121-92-8
|
Linagliptin iMpurity G
|
利拉利汀杂质G
|
668270-11-9
|
Linagliptin Impurity K
|
利格列汀杂质K
|
1638744-06-5
|
Ethyl4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate
|
2-丙基-1H-咪唑-4,5-二羧酸二乙酯
|
144689-94-1
|
Felodipine 3,5-DiMethyl Ester
|
4-(2',3'-二氯苯基) -2,6-二甲基-1,4-二氢吡啶-3,5-二羧酸二甲酯
|
91189-59-2
|
Linagliptin Impurity F
|
利格列汀杂质F
|
1673546-62-7
|
Dehydro Olmesartan
|
脱氢奥美沙坦
|
172875-98-8
|
Alfacalcidol
|
艾地骨化醇20S杂质
|
1217549-27-3
|
Olmesartan
|
奥美沙坦
|
144689-24-7
|
Ethyl4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate
|
4-(2-羟基丙-2-基)-2-丙基-1H-咪唑-5-羧酸乙酯
|
144689-93-0
|
OlmesartanEPImpurityB
|
奥美沙坦酯EP杂质B
|
849206-43-5
|
Olmesartan Medoxomil Impurity U
|
奥美沙坦酯杂质U
|
144689-23-6
|
Linagliptin N-Acetyl Impurity
|
利格列汀N-乙酰杂质
|
1803079-49-3
|
Linagliptin Impurity H
|
利格列汀杂质H
|
1646355-34-1
|
Linagliptin Impurity JX
|
利格列汀杂质JX
|
2137744-33-1
|
Trityl olmesartan
|
三苯甲基奥美沙坦酯
|
144690-92-6
|
FALECALCITRIOL
|
氟骨化醇
|
83805-11-2
|
Olmesartan MedoxomiI Impurity C
|
奥美沙坦酯C
|
87956-26-2
|
1H-Indene-1-pentanol, octahydro-4-hydroxy-ε,7a-dimethyl-α,α-bis(trifluoromethyl)-, (εR,1R,3aR,4S,7aR)-
|
氟骨化醇CD环起始物料
|
2454249-03-5
|
ethyl 2-(4-hydroxyphenyl)-4-methyl thiazole-5-carboxylate
|
2-(4-羟基苯基)-4-甲基噻唑-5-羧酸乙酯
|
161797-99-5
|
Olmesartan intermediate impurity IV
|
咪唑单乙酯杂质IV
|
1092980-84-1
|
Methyl 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylate
|
2-(3-氰基-4-异丁氧基苯基)-4-甲基噻唑-5-甲酸甲酯
|
923942-34-1
|
Febuxostat Impurity 8
|
非布索坦 杂质8
|
144060-62-8
|
ETHYL 2-(3-FORMYL-4-ISOBUTOXYPHENYL)-4-METHYLTHIAZOLE-5-CARBOXYLATE
|
2-(3-醛基-4-异丁氧基苯基)-4-甲基噻唑-5-甲酸乙酯
|
161798-03-4
|
Febuxostat Descyano Impurity
|
非布索坦杂质E
|
1206550-99-3
|
4-Hydroxyisophthalonitrile
|
2,4-二氰基苯酚
|
34133-58-9
|
Ethyl2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylate
|
2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸乙酯
|
160844-75-7
|
4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylic acid
|
4-(2-羟异丙基)-2-丙基-1H-咪唑-5-甲酸
|
144690-04-0
|
Olmesartan Impurity 58
|
奥美沙坦杂质58
|
2190488-06-1
|
2-[3-(AMinocarbonyl)-4-(2-Methylpropoxy)phenyl]-4-Methyl-5-thiazolecarboxylic Acid
|
非布索坦相关物质
|
1239233-86-3
|
2-[3-Carboxy-4-(2-Methylpropoxy)phenyl]-4-Methyl-5-thiazolecarboxylic Acid
|
非布索坦杂质B
|
1239233-87-4
|
FeBuxostat Impurity 18
|
非布索坦杂质18
|
1312815-35-2
|
ethyl 2-(3,5-diformyl-4-hydroxyphenyl)-4-methylthiazole-5- carboxylate
|
非布索坦杂质39
|
2073891-59-3
|
OlMesartan interMediate iMpurity II
|
奥美沙坦酯杂质6
|
144690-07-3
|
Febuxostat Impurity 6
|
非布司他杂质6
|
1271738-74-9
|
2-(3-cyano-4-hydroxyphenyl)-4-methylthiazole-5-carboxylic acid
|
非布索坦杂质T
|
407582-48-3
|
4-(4-METHYL-1,3-THIAZOL-2-YL)PHENOL
|
2-(4-羟基苯基)-4-甲基噻唑
|
138330-01-5
|
Febuxostat Impurity 14
|
非布索坦杂质14
|
1335202-60-2
|
ethyl 2-(4-(sec-butoxy)-3-formylphenyl)-4-methylthiazole-5- carboxylate
|
非布索坦杂质47
|
2375033-31-9
|
4-(1-Methylethenyl)-2-propyl-1H-Imidazole-5-carboxylic acidethylester
|
乙基-4-(丙-1-烯-2-基)-2-丙基
|
157356-73-5
|
ethyl 2-(4-butoxy-3-formylphenyl)-4-methylthiazole-5- carboxylate
|
非布索坦杂质45
|
2230270-03-6
|
5-(5-(ethoxycarbonyl)-4-methylthiazol-2-yl)-2-isobutoxybenzoic acid
|
非布索坦杂质55
|
2095166-41-7
|
5-Thiazolecarboxylic acid, 2-[3-(ethoxycarbonyl)-4-(2-methylpropoxy)phenyl]-4-methyl-
|
非布索坦杂质49
|
2476465-11-7
|
2-(4-HYDROXY-PHENYL)-4-METHYL-THIAZOLE-5-CARBOXYLIC ACID
|
非布索坦杂质1
|
886501-78-6
|
4-(1-Hydroxy-1-methylpropyl)-2-propyl-1H-Imidazole-5-carboxylic acidethylester
|
咪唑单乙酯杂质I
|
172875-53-5
|
Febuxostat Impurity 7
|
非布司他杂质7
|
1350352-70-3
|
Febuxostat Impurity 130
|
Febuxostat Impurity 130
|
1643131-93-4
|
2-(2-Hydroxyphenyl)-4-methyl-5-thiazolecarboxylic acid ethyl ester
|
非布索坦中间体杂质
|
118485-48-6
|
Olmesartan Impurity 9
|
奥美沙坦杂质9
|
849206-42-4
|
ethyl 2-(3-carbamoyl-4-isobutoxyphenyl)-4-methylthiazole-5- carboxylate
|
非布索坦杂质54
|
1346238-15-0
|
Febuxostat Impurity 32 HCl
|
非布司他杂质32 HCL
|
1267681-15-1
|
Levalbuterol Related Compound E (30 mg) (alpha-[{(1,1-Dimethylethyl)amino}methyl]-3-(ethoxy-methyl)-4-hydroxy-benzenemethanol)
|
左沙丁胺醇相关物质E
|
754926-25-5
|
Dehydro Nifedipine N-Oxide
|
去氢硝苯地平-N-氧化物
|
88434-69-9
|
5-(methoxycarbonyl)-2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydrop yridine-3-carboxylic acid
|
硝苯地平杂质07
|
74936-71-3
|
Nifedipine
|
硝苯地平杂质
|
17438-14-1
|
vildagliptin Impurity F
|
维格列汀杂质F
|
1789703-36-1
|
methyl (Z)-2-(2-nitrosobenzylidene)-3-oxobutanoate
|
硝苯地平EP杂质C
|
39562-27-1
|
Vildagliptin IMpurity 2 (Mixture of DiastereoMers)
|
维格列汀杂质B
|
1036959-23-5
|
Norfloxacin Impurity 6
|
诺氟沙星杂质6
|
126192-88-9
|
diethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5- dicarboxylate
|
硝苯地平杂质08
|
21829-26-5
|
Nifedipine Impurity 21
|
硝苯地平杂质21
|
80742-13-8
|
Salbutamol EP Impurity B
|
沙丁胺醇EP杂质B
|
96948-64-0
|
Nifedipine Impurity E
|
硝苯地平杂质E
|
114709-68-1
|
DehydroNifedipine
|
4 - (2硝基苯基)-2,6 -二甲基吡啶-3,5二羧酸二甲酯
|
67035-22-7
|
1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic Acid 3-(2-Cyanoethyl) 5-Methyl Ester
|
乐卡地平杂质
|
75130-24-4
|
2,6-Dichloro-4,8-dipiperidinopyrimidino[5,4-d]pyrimidine
|
2,6-二氯-4,8-二哌啶子基嘧啶并[5,4-D]嘧啶
|
7139-02-8
|
Vildagliptin carboxy acid metabolite
|
维格列汀杂质
|
565453-40-9
|
Dipyridamole EP Impurity C
|
双嘧达莫EP杂质C
|
54093-92-4
|
Levalbuterol Related Compound C (30 mg) (alpha-[{(1,1-Dimethylethyl)amino}methyl]-4-hydroxy-3-(methoxymethyl)-benzenemethanol)
|
左沙丁胺醇相关物质C
|
18910-70-8
|
vildagliptin Impurity R
|
维格列汀杂质R
|
1803168-09-3
|
m-Nifedipine
|
4-(间硝基苯基)-2,6-二甲基-1,4-二氢-3,5-吡啶二羧酸二甲酯
|
21881-77-6
|
Dehydronitrosonifedipine
|
脱氢亚硝苯地平
|
50428-14-3
|
4-CHLOROPHTHALIC ACID MONOSODIUM SALT
|
4-氯邻苯二甲酸单钠盐
|
56047-23-5
|
Dipyridamole EP Impurity D
|
双嘧达莫EP杂质D
|
1176886-12-6
|
3-ethyl 5-methyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine- 3,5-dicarboxylate
|
硝苯地平杂质06
|
53055-15-5
|
Nifedipine Impurity 7
|
硝苯地平杂质7
|
80742-11-6
|
Nimodipine Related Compound B
|
尼莫地平相关物质B
|
70172-96-2
|
Nonivamide
|
辣椒碱
|
2444-46-4
|
Dipyridamole EP Impurity F
|
双嘧达莫EP杂质F
|
60286-30-8
|
Nimodipine EP Impurity B
|
尼莫地平EP杂质B
|
21881-78-7
|
dimethyl 2,6-dimethyl-4-(4-nitrophenyl)-1,4-dihydropyridine-3,5-dicarb oxylate
|
贝尼地平杂质B
|
21829-09-4
|
Dipyridamole EP Impurity B
|
双嘧达莫EP杂质B
|
16908-47-7
|
Dipyridamole EP Impurity A
|
双嘧达莫EP杂质A
|
16982-40-4
|
N-DesMethyl DiphenhydraMine Hydrochloride
|
2-(二苯基甲氧基)-N-甲基乙胺盐酸盐
|
53499-40-4
|
Nitrendipine EP Impurity C
|
尼群地平EP杂质C
|
21829-28-7
|
Vildagliptin (2R)-Isomer
|
维格列汀杂质1
|
1036959-27-9
|
vildagliptin Impurity C
|
维格列汀杂质C
|
565453-39-6
|
vildagliptin Impurity E
|
维格列汀杂质E
|
1789703-37-2
|
Cerium silicide
|
硅化铈
|
12014-85-6
|